2World Health Organization. Global tuberculosis control: epidemiology,strategyfinaneing: WHO report 2009[R]. Geneva World Health Organization, 2008 (WHO/HTM/ TB/2009. 411).
3World Health Organization. Anti-tuberculosis drug resist- ance in the world fourth global report[R]. Geneva: World- Health Organization,2008(WHO/HTM/TB/2008. 394).
3World Health Organization. Anti-tuberculosis drug resistance in the world fourth global report [ R ]. Geneva: World Health Organiza- tion ,2008, ( WHO/HTM/TB/2008.394 ).
4Abdelaal A ,E1-Ghaffar HA ,Zaghloul MH, et al. Genotypic detec- tion of rifampicin and isoniazid resistant Mycobacterium tubercu- losis strains by DNA seqencing:a randomized trial [ J ]. Ann Clin Microbiol Antimicrob, 2009,8 ( 4 ) : 243-248.
5World Health Organization. Guidelines for theprogrammatic man- agement of drug-resistant tuberculosis: emergency update 2008 [ C ]. Geneva: World Health Organization,2008.
6Conde MB, Efron A, Loredo C, et al. Moxifloxacin Versus etham- butol in the initial treatment of tuberculosis:a double-blind, ran- domized, Controlled phase Ⅱ trial [ J ]. Lancet, 2009, 373 (9670) : 1183-1189.
7Caminero JA, Sotgiu C, Zunila A, et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis [ J ]. Laneel Infect Dis ,2010,10 (9) :621-629.
8Hugonnet JE, Tremblay LW, Boshoff H, et al. Meropenem-clavu- lanate is effective against extensively drugresistant Mycobaeterium tuberculosis [ J ]. Science,2009,323 (5918) : 1215-1218.
